With the development of advanced lithium ion batteries, electrode materials with higher capacity are urgently in demand. With respect to the anode materials, Sn-based alloy materials with high theoretical capacity (990 mAh/g) have the potential to replace the traditional, low capacity carbon-based materials. However, the practical application of Sn-based anode materials is severely retarded due to the poor cycling stability of electrode, which is believed to be caused by the pulverization of active particles resulting from the large volume of Sn during lithiation/delithiation process. The Sn-Co-C ternary alloy with amorphous or nano microstructure can overcome this problem and therefore display attractive electrochemical performance, including high capacity and good cycle stability. In the present work, amorphous Sn 30 Co 30 C 40 alloy material was synthesized through a simple and scalable two-step method (carbothermal reduction-high energy ball milling method). CoSn 2 alloy was firstly prepared by the carbothermal reduction route from low cost metal oxide and activated carbon. Then the prepared CoSn 2 were mixed with metal cobalt and graphite in a molar ratio of 3∶3∶8 via a high energy ball milling process to synthesize the final Sn 30 Co 30 C 40 material. The preferential synthesis of CoSn 2 alloy was important to get Sn 30 Co 30 C 40 material with much smaller CoSn grain dispersed in carbon matrix and thus critical to the better electrochemical performance. XRD, SEM, TEM, HR-TEM, S-TEM and electrochemical tests were used to evaluate the structure and electrochemical performance of the CoSn 2 and Sn 30 Co 30 C 40 materials. The synthesized Sn 30 Co 30 C 40 material displayed micro-sized particle morphology, which in fact was composed of 10 nm CoSn grains distributed well in amorphous carbon matrix. The Sn 30 Co 30 C 40 material showed high specific capacity of 550 mAh/g with an initial coulombic efficiency of 80%, good cycling stability and excellent rate-capability. The specific capacity of 430, 380, 280 mAh/g could be achieved at the rate of 1 C, 2 C and 5 C, respectively.

Antimicrobial peptides, small molecular weight proteins with broad spectrum antimicrobial activity, play important roles in plant defense responses. The open-reading-frame sequence of AcAMP-sn was synthesized and used to construct the gene transformation vector pAHC25::AcAMP-sn, in which AcAMP-sn gene was driven by maize ubiquitin promoter and should be highly expressed in monocot plants. The vector pAHC25::AcAMP-sn DNA was introduced into Yangmai 18 via particle bombardment. AcAMP-sn transgenic wheat plants were subjected to PCR, semi-RT-PCR, Q-RT-PCR analyses, and disease response assessments. PCR analyses revealed that the introduced gene AcAMP-sn could be stably inherited in five transgenic wheat lines from T 0 to T 4 generations. Semi-RT-PCR and Q-RT-PCR analyses showed that the AcAMP-sn gene was highly expressed in transgenic wheat lines compared with untransformed Yangmai 18. Based on disease response assessments for T 4 generations, the significantly enhanced-resistance to take-all accompanied with decreased fungal abundance, in the five independent AcAMP-sn transgenic lines. Over-expression of AcAMP-sn gene in transgenic wheat plants confers increased resistance to wheat take-all.

Objective: To investigate the causes and treatment of congenital absence of clotting factor VII. Method: The clinical data of one infant with the disease of congenital absence of clotting factor VII in our department were retrospectively analyzed. Result: The infant was transferred to neonatal ICU because of the skin bleeding for no apparent reason. The determination of coagulation factor VII was C 0.5%, revealing the coagulation factor VII deficiency. The coagulation factor VII C of the infant's parents and sister was respectively 28.5%, 31.0% and 25.2%, indicating the relationship with genetic factors. After repeated infusion of fresh frozen plasma and prothrombin complex, the infant recovered and was discharged from hospital. Conclusion: In clinical work, coagulant function abnormality of neonatal repeatedly, we should check the clotting factor as soon as possible in order to avoid missed diagnosis, misdiagnosis and delay treatment.